Your browser is no longer supported. Please, upgrade your browser.
EDSA Edesa Biotech, Inc. daily Stock Chart
Edesa Biotech, Inc.
Index- P/E- EPS (ttm)-2.13 Insider Own7.40% Shs Outstand7.14M Perf Week-5.10%
Market Cap38.56M Forward P/E- EPS next Y- Insider Trans- Shs Float3.16M Perf Month-18.80%
Income-5.50M PEG- EPS next Q- Inst Own31.30% Short Float0.19% Perf Quarter12.50%
Sales0.20M P/S192.78 EPS this Y48.90% Inst Trans4.78% Short Ratio0.03 Perf Half Y-14.29%
Book/sh1.44 P/B3.75 EPS next Y- ROA-56.80% Target Price2.00 Perf Year-31.82%
Cash/sh- P/C- EPS next 5Y- ROE-61.50% 52W Range3.28 - 17.40 Perf YTD-1.10%
Dividend- P/FCF- EPS past 5Y38.30% ROI-44.90% 52W High-68.79% Beta-0.53
Dividend %- Quick Ratio6.90 Sales past 5Y-17.20% Gross Margin-31.00% 52W Low65.55% ATR0.58
Employees25 Current Ratio7.00 Sales Q/Q- Oper. Margin- RSI (14)48.83 Volatility9.44% 9.41%
OptionableNo Debt/Eq0.00 EPS Q/Q86.70% Profit Margin- Rel Volume0.32 Prev Close5.40
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume206.21K Price5.43
Recom- SMA20-7.38% SMA504.16% SMA200-11.43% Volume60,070 Change0.56%
Oct-21-19 07:30AM  Edesa Biotech Enrolls First Patient in Phase 2b Dermatitis Study ACCESSWIRE
Aug-29-19 08:30AM  Edesa Biotech to Present at H. C. Wainwright Global Investment Conference ACCESSWIRE +7.37%
Aug-14-19 04:05PM  Edesa Biotech Reports Quarterly Financial Results ACCESSWIRE
Jul-25-19 07:30AM  Edesa Biotech Completes Manufacturing for Upcoming Dermatitis Study ACCESSWIRE
Jun-20-19 12:12PM  Edesa Biotech (EDSA) Stock Rockets Higher on Dermatitis Study Approval InvestorPlace +74.94%
08:26AM  Edesa Biotech stock rockets 140% after FDA gives go-ahead to early-stage trial MarketWatch
07:30AM  Edesa Biotech Receives Approval to Proceed with U.S. Clinical Study CNW Group
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the development and advancement of treatments for dermatological and gastrointestinal indications. Its lead product candidate is EB01, a non-steroidal anti-inflammatory molecule to treat chronic allergic contact dermatitis. The company was founded in 2015 and is headquartered in Markham, Canada.